A
ALKemist Bio
ALKemist Bio is creating TCR-T cells targeting ALK antigens in ALK-positive cancer cells, with a focus on non-small cell lung cancer
About ALKemist Bio
Alkemist Bio is a biotechnology company focused on developing next-generation cell therapies for patients with ALK positive cancers, which include non-small cell lung cancer, brain, and breast cancers. The company aims to address the challenges of resistance and low progression-free survival in ALK positive patients by offering innovative cell therapy solutions. Alkemist Bio operates in the oncology market, serving healthcare providers and patients who require advanced cancer treatments. The business model revolves around research and development of proprietary cell therapies, which are then commercialized through partnerships with healthcare institutions and pharmaceutical companies. Revenue is generated through licensing agreements, sales of therapies, and potential milestone payments from partners.
Source: Dealroom company dataAt a glance
- Founded
- 2023
- Headquarters
- Turin, Italy
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Investors' club
Claris Ventures
Italian Angels for Growth
LIFTT
Simon Fiduciaria
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ALKemist Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ALKemist Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.